Invenra to Present Preclinical Data on INV322, A Next Generation Tumor Treg Depleter
MADISON, Wis.–(BUSINESS WIRE)–Invenra, a company developing next generation therapeutic antibodies, announced today that Chief Scientific Officer Daniel Pereira, Ph.D., will present preclinical data supporting the ongoing development of INV322, an antibody-based cancer therapeutic. The preclinical research findings will be presented at the 13th Annual World Bispecific Summit, Thursday, September 22nd, 2022 and at the Immuno-Oncology … [Read more…]
